Analysis of Selective Serotonin Reuptake Inhibitors Associated with QT Prolongation and Torsade de Pointes Adverse Events Based on Data Mining Methods
PAN Ling-yun1,2, TANG Xue-wen1, JI Huan-huan2,JIA Yun-tao2*
1. College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; 2. Department of Pharmacy, Children��s Hospital of Chongqing Medical University, Chongqing 400014, China
Abstract��OBJECTIVE To excavate and evaluate the risk signals of QT prolongation and torsade de pointes(TdP) induced by selective serotonin reuptake inhibitors(SSRIs), provide references for clinical use. METHODS Data from FDA adverse event reporting system (FAERS, from January 2004 through June 2018) were analyzed for each SSRIs, including fluoxetine, sertraline, citalopram, escitalopram, paroxetine, and fluvoxamine. When QT prolongation and TdP cases were identified using preferred terms (PT) and standardised MedDRA queries (SMQ), three different data mining algorithms were used to detect signalsreporting odds ratio (ROR), medicines and healthcare products regulatory agency (MHRA), and bayesian confidence popagation neural network (BCPNN), if all the three algorithms were positive, suggesting the generation of signals. RESULTS A total of 3 912 reports of QT prolongation and TdP associated with SSRIs were retrieved through the SMQ. Among which, more females than males(2 349 vs. 1 150), mainly aged 18-44 and 45-64 years, and 90.64% were serious adverse events. The signals were found for fluoxetine, sertraline, citalopram, escitalopram, paroxetine and fluvoxamine at the SMQ level, the RORs (95%CI) were 5.25(4.79-5.76), 2.08(1.79-2.27), 2.86(6.32-7.44), 3.41(3.03-3.84), 2.09(1.84-2.37) and 10.44(8.17-13.33) respectively; the PRRs (X2) were 5.20(1 494.43), 2.01(140.41), 6.77(2 911.71), 3.93(462.34), 2.09(136.58) and 10.21(538.26) respectively; the ICs (IC-2SD) were 2.15(2.12), 1.54(1.52), 2.67(2.65), 2.34(2.31) 1.14(1.12) and 3.16(3.10) respectively. Analysis of the PT included in the SMQ for TdP/QT prolongation, except paroxetine was only detected electrocardiogram QT prolonged signal, all the other SSRIs were detected electrocardiogram QT prolonged and TdP signals. CONCLUSION QT prolongation may be a SSRIs class effect, but TdP just for fluoxetine, sertraline, citalopram, escitalopram and fluvoxamine. Clinical staff should pay more attention to the differences in adverse drug reaction related to SSRIs, and take pertinence measure to prevent.
������, ��ѧ��, ������, ������. ���������ھ�����ѡ����5-��ɫ������ȡ���Ƽ����QT�����ӳ������Ťת�������Ķ������źŵķ����о�[J]. �й�ҩѧ��־, 2019, 54(10): 828-833.
PAN Ling-yun, TANG Xue-wen, JI Huan-huan,JIA Yun-tao. Analysis of Selective Serotonin Reuptake Inhibitors Associated with QT Prolongation and Torsade de Pointes Adverse Events Based on Data Mining Methods. Chinese Pharmaceutical Journal, 2019, 54(10): 828-833.
INSEL T R, WANG P S. Rethinking mental illness. JAMA, 2010, 303(19):1970-1971.
[2]
PRATT L A, BRODY D J, GU Q. Antidepressant use among persons aged 12 and over: United States, 2011-2014. NCHS Data Brief, 2017(283):1-8.
[3]
QASEEM A, BARRY M J, KANSAGARA D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American college of physicians.. Ann Inter Med, 2016, 164(5):350-359.
[4]
OSTACHER M J, TANDON R, SUPPES T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry, 2015, 77(7):920-926.
[5]
BAUER M, SEVERUS E, MOLLER H J, et al. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract, 2017,21(3):166-176.
[6]
STOCK E M, ZEBER J E, MCNEAL C, et al. Psychotropic pharmacotherapy associated with QT prolongation among veterans with posttraumatic stress disorder. Ann Pharmacother, 2018, 52(9):838-848.
[7]
CASTRO V M, CLEMENTS C C, MURPHY S N, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ,2013,346: f288.
[8]
BEACH S R, KOSTIS W J, CELANO C M, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry,2014, 75(5):e441-449.
[9]
REVOL B, JULLIANDESAVES I, TAMISIER R, et al. Ticagrelor and central sleep apnea. J Am Coll Cardiol, 2018, 71(20):2378-2379.
[10]
MONTASTRUC F, SALVO F, ARNAUD M, et al. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase�j. Drug Saf, 2016, 39(7):689-696.
[11]
ZONG X, WANG Y L. On open FDA and enlightenments for data management of food and drug administration in China . Chin Pharm Aff(�й�ҩ��), 2017, 31(9):976-979.
[12]
HOU Y F, REN J T, JIANG J, et al. Study of adverse drug reaction signal detection . Chin J Pharmacoepidemiol(ҩ�����в�ѧ��־), 2010, 19(7):369-372.
[13]
PAN J L, LIU Z Y, CHEN J, et al. Signal mining and analysis of adverse drug reactions caused by rituximab . Chin Pharm J(�й�ҩѧ־),2016,51(22):1976-1981.
[14]
REN J T, WANG S F, HOU Y F, et al. Comparative study on the common signal detection methods of adverse drug reaction . Chin J Pharmacov(�й�ҩ�ﾯ��), 2011, 8(6):356-359.
[15]
PEARSON R K, HAUBEN M, GOLDSMITH D I, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform, 2009, 78(12):97-103.
[16]
SHI W T, YE X F, ZHANG T Y, et al. Problems and analytic strategies in adverse drug reaction signal detection . Chin J Pharmacoepidemiol(ҩ�����в�ѧ��־), 2014, 23(7):437-440.
[17]
FUNK K A, BOSTWICK J R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother, 2013, 47(10):1330-1341.
[18]
WENZEL-SEIFERT K, WITTMANN M, HAEN E. Torsade de pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry, 2010, 43(7):279-281.
[19]
EKHART C, VAN F H, SCHOLLl J, et al. Sex differences in reported adverse drug reactions of selective serotonin reuptake inhibitors. Drug Saf, 2018, 41(7):677-683.
[20]
ARRHYTHMIA GROUP, CHINESE SOCIETY OF CARDIOLOGY. Prevention and treatment of acquired long QT syndrome . Chin J Cardiac Pacing Electrophysiol(�й����������ĵ�������־), 2010, 24(6):471-479.
[21]
SAKAEDA T, KADOYAMA K, MINAMI K, et al. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci, 2014, 11(5):461-465.
[22]
TATONETTI N P, FERNALD G H, ALTMAN R B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012, 19(1):79-85.
2019, Vol. 54 
